{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:04:02Z","timestamp":1792728242653,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s15010-020-01510-8","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T20:02:18Z","timestamp":1598731338000},"page":"355-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5453-2799","authenticated-orcid":false,"given":"S. Alexander","family":"Winans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richelle L.","family":"Guerrero-Wooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Garret","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Forland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"1510_CR1","unstructured":"US Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. CDC. 2013.\u00a0https:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf. Accessed 29 Aug 2019."},{"key":"1510_CR2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1017\/ice.2016.174","volume":"37","author":"LM Weiner","year":"2016","unstructured":"Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014. Infect Control Hosp Epidemiol. 2016;37:1288\u2013301.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1510_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"1510_CR4","unstructured":"Zerbaxa [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2019."},{"key":"1510_CR5","first-page":"1","volume":"14","author":"M Ramanan","year":"2015","unstructured":"Ramanan M, Lipman J, Shorr A, Shankar A. A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections. BMC Infect Dis. 2015;14:1\u201312.","journal-title":"BMC Infect Dis"},{"key":"1510_CR6","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019."},{"key":"1510_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","volume":"49","author":"A Dinh","year":"2017","unstructured":"Dinh A, Wyplosz B, Kern\u00e9is S, Lebeaux D, Bouchand F, Duran C, et al. Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2017;49:782\u20133.","journal-title":"Int J Antimicrob Agents"},{"key":"1510_CR8","doi-asserted-by":"publisher","first-page":"e00451","DOI":"10.1016\/j.idcr.2018.e00451","volume":"14","author":"A Frattari","year":"2018","unstructured":"Frattari A, Savini V, Polilli E, Cibelli D, Talamazzi S, Bosco D, et al. Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: Case report and review of the literature. IDCases. 2018;14:e00451.","journal-title":"IDCases"},{"key":"1510_CR9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1128\/AAC.44.5.1356-1358.2000","volume":"44","author":"J Alban\u00e8se","year":"2000","unstructured":"Alban\u00e8se J, L\u00e9one M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000;44:1356\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1510_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijantimicag.2013.08.019","volume":"43","author":"H Huang","year":"2014","unstructured":"Huang H, Huang S, Zhu P, Xi X. Continuous versus intermittent infusion of cefepime in neurosurgical patients with post-operative intracranial infections. Int J Antimicrob Agents. 2014;43:68\u201372.","journal-title":"Int J Antimicrob Agents"},{"key":"1510_CR11","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10096-019-03573-4","volume":"38","author":"B Pilmis","year":"2019","unstructured":"Pilmis B, Petitjean G, Lesprit P, Lafaurie M, El Helali N, Le Monnier A, et al. Continuous infusion of ceftolozane\/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2019;38:1457\u201361.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1510_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/jac\/dkf130","volume":"50","author":"VH Tam","year":"2002","unstructured":"Tam VH. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002;50:425\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1510_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.12.018","volume":"45","author":"SL Aitken","year":"2015","unstructured":"Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, et al. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin\/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015;45:541\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"1510_CR14","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1128\/AAC.00294-06","volume":"51","author":"C Li","year":"2007","unstructured":"Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51:1725\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"1510_CR15","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","volume":"49","author":"VH Tam","year":"2005","unstructured":"Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:4920\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1510_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jinf.2006.09.004","volume":"54","author":"SY Lee","year":"2007","unstructured":"Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with extended spectrum \u03b2-lactamase (ESBL) and non-ESBL infections. J Infect. 2007;54:463\u20138.","journal-title":"J Infect"},{"key":"1510_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1128\/AAC.41.5.987","volume":"41","author":"R Nau","year":"1997","unstructured":"Nau R, Kinzig-Schippers M, S\u00f6rgel F, Schinschke S, R\u00f6ssing R, M\u00fcller C, et al. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. Antimicrob Agents Chemother. 1997;41:987\u201391.","journal-title":"Antimicrob Agents Chemother"},{"key":"1510_CR18","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1046\/j.1469-0691.2003.00786.x","volume":"9","author":"U Frank","year":"2003","unstructured":"Frank U, Mutter J, Schmidt-Eisenlohr E, Daschner FD. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Clin Microbiol Infect. 2003;9:1128\u201332.","journal-title":"Clin Microbiol Infect"},{"key":"1510_CR19","first-page":"49","volume":"32","author":"HY Kuo","year":"2009","unstructured":"Kuo HY, Der WF, Yen YF, Lin ML, Liu CY. In vitro activities of piperacillin or cefoperazone alone and in combination with \u03b2-lactamase inhibitors against Gram-negative bacilli. New Microbiol. 2009;32:49\u201355.","journal-title":"New Microbiol"},{"key":"1510_CR20","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1128\/AAC.38.10.2351","volume":"38","author":"AH Strayer","year":"1994","unstructured":"Strayer AH, Gilbert DH, Pivarnik P, Medeiros AA, Zinner SH, Dudley MN. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994;38:2351\u20136.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-020-01510-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T23:44:10Z","timestamp":1630194250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-020-01510-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1510"],"URL":"https:\/\/doi.org\/10.1007\/s15010-020-01510-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,29]]},"assertion":[{"value":"22 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared no conflicts of interest for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}